Demarest Lloyd Jr. Foundation Report issue

Foundation Phase 4

Organization Overview

First Clinical Trial
2019
NCT03757585
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Demarest Lloyd Jr. Foundation

Active Ingredients

Drugs in Phase 4 Trials (3)

acetylcysteine (mucomyst) (1 trial)

myoinositol (1 trial)

omega-3 fatty acids (omacor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Autism Spectrum Disorder (Phase 4)

Autistic Disorder (Phase 4)

Child Development Disorders, Pervasive (Phase 4)

Disease (Phase 4)

Learning Disabilities (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial APIs: 3